The "Elevate" by MAPS Podcast

Welcome to Part 2 of the MAPS Field Medical Focus Area Working Group's two-part podcast series entitled "Communicating the Value of Field Medical". In this second episode, experts from the FAWG will discuss Field Medical with the following goals in mind:The participant will be able to learn tips on how to explain the Field Medical value proposition to external stakeholdersLearn how to adapt the proposition when you have just a short time in which to explain itLearn how to adapt the proposition to connect to medical customers more quickly

Welcome to Part 1 of the MAPS Field Medical Focus Area Working Group's two-part podcast series entitled "Communicating the Value of Field Medical". In this first episode, experts from the FAWG will discuss Field Medical with the following goals in mind:To help the listener communicate the value of Field Medical to internal stakeholdersExplain how to integrate the qualitative and quantitative measures when communicating Field Medical value to internal stakeholdersDiscuss how to build relationships and engage with internal stakeholders

In a post-COVID world, HCPs want to access industry information through self-service content that is available anytime, anywhere — before they engage with representatives from the company. Most companies are aware of this trend. However, most industry organizations are not equipped with the modular content and online platforms needed to deliver this Netflix-like engagement. Here MAPS speaks with Bozidar Jovicevic, MD, MBA, former pharma executive, CEO and cofounder of Evermed, about best practices for gathering content (beyond simply creating it yourself!), and making content accessible in modern, personalized platforms.

One of the great challenges in Medical Affairs is understanding our opinion and communication networks. Over the last few years, the diversity of stakeholders involved in communicating, advocating, treating and responding to our work has become more complex and dynamic. At the same time, communication routes have proliferated and opened, taking us away from our traditional channels. This wealth of data can be overwhelming. In this podcast, Carlos Areia and Mike Taylor - two data specialists at Digital Science - discuss the ways in which Medical Affairs professionals can use this data to discover your next generation of researchers, those influencers whose voices are heard on Twitter, and how your KOLs are interacting with others online, and which publications they're discussing.

Today’s podcast objectives are for listeners to better understand: What innovative content is in the context of Medical Information Expectations of HCPs in accessing innovative contentAnd key learnings in the transition toward the use of more innovative content.

During Covid, many companies developed capabilities to provide eLearning resources, both for internal training and for external education. In this episode, MAPS speaks with Sucharita Kundu, Senior Content Strategist at Wiley and Professor Michael Kirby, currently the Editor of Trends in Urology & Men’s Health about best practices for eLearning development and publication. We've transitioned from eLearning provided from a company-centric perspective to courses designed based on deep understanding of an audience's content needs and interaction preferences. This episode teaches listeners to create eLearning resources that are relevant, credible and evidence-based. 

The goal of all Medical Affairs activities is to improve patient outcomes. That said, until recently, we have measured our progress toward this goal by fairly distant proxy — for example, tracking the number of MSL/HCP interactions as a proxy for providing education that we hope will result in changes in clinical practice. In this episode of the MAPS podcast series, "Elevate", Ariel Katz, co-Founder and CEO of H1, provides a more linear and streamlined vision for how Medical Affairs can impact patient outcomes — and how to measure the results of our actions.

The role of real-world evidence (RWE) in Medical Affairs has greatly evolved in the last few years. The clinical evidence regarding the potential benefits or risks of a therapy generated from data relating to patient health or the delivery of health care can add value at every stage of a product’s lifecycle. RWE can not only help support a product’s safe and appropriate use in a post-approval setting, but the data can also inform innovation, trial design, personalized medicine, regulatory filings and optimize decision-making for better patient outcomes. In this episode, we hear from RWE and industry experts on the importance of early alignment of your evidence generation plan and medical strategy and how to integrate RWE into your publication plan.

Conference prep requires more than placing publications, securing booth space and scheduling as many KOL meetings as possible. Here we speak with Chris Medieros, Director of Strategic Insights, H1, about how to maximize your organization's presence and impact at congresses, including how to plan strategically across the workflow of KOL interactions.

In today's episode of the MAPS "Elevate" podcast, we'll be looking at considerations for Medical Affairs in Rare Disease and Gene Therapy and reviewing the following questions:How do you the see the role of Medical Affairs evolving in the era of advance therapeutics like gene therapy, often investigated for rare disorders? Are there specialized skillsets MA professionals need to be successful in this area? What are three major differences in approach to Med Affairs planning in rare disease, whether or not there is a gene therapy involved? From your experience, what are the biggest hurdles for Med Affairs professionals educating HCPs on gene therapy? It sounds really exciting in concept, but does the reality differ in practice? What advice is there for Med Affairs colleagues wanting to work in either rare disease or gene therapy? Are there specialized roles coming up in this space, different from current roles?